Top strategies in the management of advanced renal cell carcinoma (RCC)
Activity Description / Statement of Need:
In this online, self-learning activity:
Renal cell carcinoma (RCC) is a cancer that is borne and takes root in the nephrons. It is responsible for most cancers of the kidney and renal pelvis, which occur in 79,000 people and account for close to 14,000 deaths in the U.S. per year. The five-year survival rate is 93% for patients with early stages of the disease. However, in patients with advanced or metastatic disease, the five-year survival is 14%, representing an area of ongoing clinical need. Treatment selection in advanced, clear cell RCC treatment depends on prognostic scoring and may include mono- or combination therapy with immunotherapy and an antiangiogenic agent, and many of the same agents are used to treat advanced, non-clear cell RCC.
Target Audience:
HCPs including: Medical oncologists and urologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with RCC.
Cost: Free
View Offer chevron_rightDetails
Activity Description / Statement of Need:
In this online, self-learning activity:
Renal cell carcinoma (RCC) is a cancer that is borne and takes root in the nephrons. It is responsible for most cancers of the kidney and renal pelvis, which occur in 79,000 people and account for close to 14,000 deaths in the U.S. per year. The five-year survival rate is 93% for patients with early stages of the disease. However, in patients with advanced or metastatic disease, the five-year survival is 14%, representing an area of ongoing clinical need. Treatment selection in advanced, clear cell RCC treatment depends on prognostic scoring and may include mono- or combination therapy with immunotherapy and an antiangiogenic agent, and many of the same agents are used to treat advanced, non-clear cell RCC.
Target Audience:
HCPs including: Medical oncologists and urologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with RCC.